Yiling Pharma owns three manufacturing sites for API and Formulation products. Yiling’s technical team drives projects from pre-formulation development to commercial scale manufacture,and have finished over 30+ site transfer projects,10+ new drug projects of small batches for clinical trial,and submitted 13 ANDAs to US FDA.The annual capacity of Formulation sites exceeds 6.4 billion units,and will expand to 26.4 billion units recently,and capability of injection(0.42 billion vial/ampoule)will join soon. As a wholly-owned subsidiary of Yiling Group,Yiling Pharmaceutical Ltd.is solely responsible for the innovative development of chemical drugs.
Three Sectors
Yiling Pharma is managed by strong team of R&D,Production,Quality,Marketing & Sales.Management team possess multinational pharma corporation background and excellent expertise.Yiling ranks in one of the largest China’s enterprises exporting finished drugs to regulated market.Facilities have been certified by US FDA, MHRA,China NMPA,TGA,Health Canada and Medsafe for many times.
Milestones
